ClinicalTrials.gg
CompletedNCT05721287Updated Nov 26, 2025

A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

A Phase 1 interventional study of SBS-1000 and Placebo in Pain and Acute Pain, sponsored by Sparian Biosciences, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-26.

Primary conditionAcute PainRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acute Pain
Why
  1. The study's listed conditions name Acute Pain, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sparian Biosciences, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.

Enrollment
215th of 322
48 · median 86
Started
2023
with 21 others
Phase 1
27 of 353
3 open now
Registered
278th of 353
by date

Among the 353 studies in Acute Pain with a site in United States, this one is the 215th largest by enrollment of the 322 interventional ones that give a count, is one of 22 that started in 2023, is one of 27 in phase 1, and was the 278th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Acute Pain with a site in United States, or all of them as a file.
02

Study summary

This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.

Read the detailed description

This study will be a single-center (clinical research unit), double-blind, placebo-controlled, randomized, adaptive, single-ascending dose study receiving either Investigational Product (IP [SBS-1000]) or placebo IV infusion. Up to 56 subjects will be randomized.

A total of 6 ascending dose cohorts will be used to assess the MTD of SBS-1000. Each cohort will be comprised of up to 8 subjects randomized 6:2 (IP:placebo). A sentinel group of 2 subjects randomized 1:1 (IP:placebo) will be used for each cohort with the sentinel group being dosed at least 48 hours prior to dosing the remaining subjects of the cohort, and contingent on the results of ongoing safety evaluation.

Blood samples will be collected over 72 hours postdose and urine samples over 48 hours postdose for pharmacokinetic (PK) assessments in all cohorts. Pharmacodynamic assessments will be performed throughout the study in cohorts 1 through 6. The sampling parameters may be adjusted based on the interim safety review.

Once the maximum tolerated dose (MTD) is established, dosing with the MTD or a lower dose, as determined by an interim safety review, an additional cohort (7) will occur to investigate the cardiodynamic effects of SBS-1000 using Holter monitoring. Cohort 7 will be comprised of 8 subjects randomized 6:2 (IP:placebo). No sentinel dosing administration will occur in this cohort.

03

Conditions studied

  • Pain
  • Acute Pain

Browse trials for

Keywords

  • Arylepoxamide
  • Safety
  • Tolerability
  • SBS-1000
  • SBS1000
  • 6TM
  • AEAr Agonist
04

In context

Acute Pain Reclassified

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

This study's enrollment of 48 is below the median of 86 across 905 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Sparian Biosciences, Inc is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Acute Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form (ICF)
  2. Healthy adult male or female, aged 18 to 59 years, inclusive, at Screening
  3. (BMI) within 18.0 kg/m\^2 to 33.0 kg/m\^2, inclusively
  4. Minimum body weight of at least 50.0 kg at Screening
  5. Willingness to comply with all study procedures
  6. If female, agrees to use an acceptable method.
  7. If male, agrees to use an acceptable contraceptive method.
  8. Healthy as determined by no findings at screening and clinic admission.
  9. Non- or ex-smoker

Exclusion criteria

Exclusion Criteria:

  1. Has a current medical condition that would affect sensitivity to cold or pain
  2. Personal or family history of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic, dermatologic, or other disease that may interfere with the study
  3. Any clinically significant illness in the 28 days prior to the first study drug administration
  4. Use of any prescription drugs in the 28 days prior to the first study drug administration, that in the opinion of an investigator would put into question the status of the participant as healthy
  5. Routine or chronic use of acetaminophen and/or nonsteroidal anti-inflammatory drugs (NSAIDs)
  6. Any clinically significant laboratory results at screening or prior to the first drug administration
  7. intake of an product within 28 days prior to study drug administration.
  8. Positive test for alcohol and/or drugs of abuse
  9. Positive for or hepatitis
  10. Donation of plasma 7 days prior to study drug administration and/or donation of blood within 56 days prior to study drug administration.
  11. Significant abnormalities
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    SBS-1000

    Investigational Product

    Drug: SBS-1000

  • Placebo comparator
    Placebo

    Normal saline (0.9% sodium chloride \[NaCl\])

    Drug: Placebo

Interventions

  • DrugSBS-1000

    SBS-1000 administered as a single continuous IV infusion over 60 minutes

    Also known as: arylepoxamide agonist

  • DrugPlacebo

    Normal saline (0.9% sodium chloride \[NaCl\]) administered as a single dose IV infusion over 60 minutes

    Also known as: sodium chloride

07

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events (AEs)

    Adverse events as assessed by electrocardiogram, vital signs, end-tidal carbon dioxide, oxygen saturation, physical examination, clinical laboratory tests, OAAS, C-SSRS, slit-lamp examination, gastrointestinal/esophageal assessment and concomitant medications

    Time frame: From start of infusion to 4 (±2) days after the last blood draw in the study

Secondary outcomes

  1. Area under the plasma concentration (AUC) and Cmax versus time curve of SBS-1000

    Assessment of systemic pharmacokinetics (PK) and urinary excretion of SBS-1000 by evaluation of AUC, Cmax, tmax, Ke t 1/2, Cl, V and Urine PK

    Time frame: From start of infusion to 72 hours post-infusion

08

Study locations

1 site
  • Altasciences Clinical Kansas
    Overland Park, Kansas 66212, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Aug 2023, 6 months.

Of 33 phase 1 interventional studies under Acute Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 17. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 10, 2023
StartActual
Jan 30, 2023
Primary completionActual
Aug 15, 2023
CompletionActual
Aug 30, 2023
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05721287
Lead sponsor
Sparian Biosciences, Inc
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Jan 30, 2023
Primary completion
Aug 15, 2023
Completion
Aug 30, 2023
Last update
Nov 26, 2025

Study contacts

Jeff Reich, MD
study director · Sparian Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion